Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

278 results about "Mucoprotein" patented technology

A mucoprotein is a glycoprotein composed primarily of mucopolysaccharides. Mucoproteins can be found throughout the body, including the gastrointestinal tract, reproductive organs, airways, and the synovial fluid of the knees. They are called mucoproteins because the carbohydrate quantity is more than 4% unlike glycoproteins where the carbohydrate quantity is less than 4%.

Isolated ackermansiella muciniphila, composition comprising same and anti-aging and / or anti-oxidation use thereof

The invention provides isolated Ackermansiella muciniphila, a composition containing the same and an anti-aging and / or anti-oxidation application of the Ackermansiella muciniphila. The Akkermansia muciniphila has the advantages that the average life and the longest life of the Akkermansia muciniphila in a nematode model can be prolonged, the movement activity, the swallowing function and the reproductive capacity of the Akkermansia muciniphila can be improved, the expression of insulin / IGF-1 pathway genes (daf-16, daf-2 and age-1), the expression of antioxidant genes (gst-4 and sod-3) and the expression of longevity related genes (sir-2.1) of the Akkermansia muciniphila can be up-regulated, and the antioxidant capacity and the heat stress tolerance of the Akkermansia muciniphila can be enhanced. It is shown that the Akkermansia muciniphila provided by the invention can be used for preparing or developing the anti-oxidation and anti-aging products, and the anti-oxidation and anti-aging products can be prepared from the Akkermansia muciniphila. The invention provides an efficient and safe solution for anti-aging and / or anti-oxidation.
Owner:MOON (GUANGZHOU) BIOTECH CO LTD

Application of Ackermania muciniphila YG2645 in improvement of glycolipid metabolism

The invention relates to application of Akkermansia muciniphila YG2645 or a derivative of the Akkermansia muciniphila YG2645 or a composition containing the Akkermansia muciniphila YG2645 to preparation of a product for improving glycolipid metabolism disorder or treating diseases or symptoms related to the glycolipid metabolism disorder. The Ackermansiella muciniphila can effectively inhibit lipid accumulation, promote GLP-1 secretion, regulate intestinal flora and regulate cholic acid, taurine and phospholipid metabolism, so that the Ackermansiella muciniphila has potential treatment potential in the aspects of regulating glycolipid metabolism disorder and treating diseases or symptoms related to the glycolipid metabolism disorder, and has better clinical application prospect and value.
Owner:BEIJING YUJING PHARM CO LTD

Application of polygonatum cyrtonema polysaccharide in preparation of medicine for treating ulcerative colitis or reducing blood glucose

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.
Owner:WANNAN MEDICAL COLLEGE +2

M. moricola for improving obesity and glucose and lipid metabolism

The application belongs to the field of intestinal microbiology, and discloses a new mucinophilic Akkermansia with improved obesity and glycolipid metabolism, wherein the mucinophilic Akkermansia strain is Akk-101 and AMY001. The preservation number of Akk-101 is CGMCC No. 40786, and the preservation number of AMY001 is CGMCC No. 46141. The Akk-101 and AMY001 strains in the application are different from standard strains in nucleotide consistency and physiological and biochemical indexes, have better acid-base tolerance and colonization capacity than the standard strains, can more effectively inhibit the accumulation of liver cell lipids, reduce the fat deposition in nematodes, and have the effects of weight loss and improvement of glycolipid metabolism, so that related products can be effectively developed based on the strains.
Owner:BEIJING QUANTIHEALTH TECH CO LTD

Culture medium and method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as carbon source

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.
Owner:JIMEI UNIV

Ackermania muciniphila YG2645 with function of regulating intestinal-immune-metabolic axis and application of Ackermania muciniphila YG2645

The invention relates to the field of microorganisms, in particular to Akkermansia muciniphila YG2645 with an intestinal tract-immune-metabolic axis regulating function, an inactivated thallus, an extract, a culture, a culture supernatant, a fermentation product and / or a fermentation supernatant of the Akkermansia muciniphila YG2645, a composition containing the Akkermansia muciniphila YG2645 and a preparation method of the composition containing the Akkermansia muciniphila YG2645 and the composition containing the Akkermansia muciniphila YG2645 and the composition containing the composition. The invention also relates to application of the compound in preparation of products for preventing and / or treating inflammatory diseases. The Akkermansia muciniphila YG2645 and related products of the Akkermansia muciniphila YG2645 have the functions of regulating and controlling immune response, regulating and controlling metabolism, regulating intestinal flora and the like, and the Akkermansia muciniphila YG2645 and the related products of the Akkermansia muciniphila YG2645 have remarkable application value and market potential.
Owner:BEIJING YUJING PHARM CO LTD

Ackermania muciniphila Akk21 with hypoglycemic capacity, and application, product and method of ackermania muciniphila Akk21

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.
Owner:WUHAN WEIKANG PROBIOTICS RES INST CO LTD

Application of Ackermania muciniphila or extracellular vesicles thereof in preparation of medicine for alleviating alcoholic ischemic necrosis of femoral head

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Application of Ackermann muciniphile in preparation of diabetic metabolic disease related renal injury products

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.
Owner:THANKCOME BIOLOGICAL SCI & TECH CO LTD

Mucin-tannic acid packaged probiotic preparation as well as preparation method and application thereof

The invention belongs to the field of biotechnology and medical configuration products, and provides a mucoprotein-tannic acid packaged probiotic preparation as well as a preparation method and application thereof. According to the preparation method disclosed by the invention, tannic acid and mucoprotein are encapsulated in escherichia coli Nissle 1917 and lactobacillus plantarum NC8, so that the mucoprotein-tannic acid encapsulated probiotic preparation is obtained. The probiotic microbial agent prepared by the invention has excellent resistance to severe environment of gastrointestinal tracts, and the adhesiveness of the probiotic microbial agent in intestinal tracts is enhanced, so that the colonization and growth of the probiotics in a mucous layer are enhanced. Meanwhile, bacterial enteritis, especially enteritis caused by enterotoxigenic escherichia coli (ETEC), can be effectively treated.
Owner:JILIN AGRICULTURAL UNIV

Preparation method of high-purity recombinant mussel mucin

The invention discloses a preparation method of high-purity recombinant mussel mucoprotein, and belongs to the technical field of recombinant protein preparation, the idea of improving target protein expression by adopting fusion protein is adopted, and fusion expression is performed on partial peptide fragments of an amino acid sequence of mytilus coruscus Mfp-3 and an amino acid sequence of common mussel preCol-D to obtain the high-purity recombinant mussel mucoprotein. The recombinant mussel mucin which is high in purity, low in endotoxin content and good in adhesion performance is obtained by combining improvement of induction, tyrosinase modification and separation and purification processes, a new thought is provided for industrial production of the recombinant mussel mucin through successful preparation of the recombinant mussel mucin, raw material support is provided for multi-field application of the recombinant mussel mucin, and the method is suitable for industrial production of the recombinant mussel mucin. The customized sequence recombinant mussel mucoprotein is prepared according to application requirements, and the application of the mussel mucoprotein in different fields is promoted.
Owner:HEFEI SHELL PARTY INNOVATIONS TECH CO LTD

Pediococcus acidilactici and application thereof in improving cerebral apoplexy, fatty liver and uric acid metabolism

ActiveCN118995541ABacteriaDigestive systemAlcohol degradationXanthine
The invention discloses pediococcus acidilactici and application thereof in improving cerebral apoplexy, fatty liver and uric acid metabolism, and belongs to the technical field of marine microorganisms. The pediococcus acidilactici NHNK-610 is preserved in the China Center for Type Culture Collection on April 25, 2024, and the preservation number of the pediococcus acidilactici NHNK-610 is CCTCC (China Center for Type Culture Collection) NO: M2024797. Experiments show; the NHNK-610 has the effects of dissolving thrombus, regulating blood coagulation factors of vascular endothelial cells, repairing aged blood vessels, promoting blood brain barriers, inhibiting Klebsiella pneumonia from generating alcohol, agglutinating Klebsiella pneumonia, inhibiting virulence genes of Klebsiella pneumonia, promoting alcohol metabolism, reducing alcohol damage, resisting alcohol, degrading uric acid, inhibiting xanthine oxidase activity, and inhibiting the activity of Klebsiella pneumonia. Uric acid excretion is promoted, and the function of colonization of mucoprotein and intestinal epithelial cells is improved through a thallus biological membrane.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Lactobacillus plantarum for relieving diarrhea caused by ETEC and application of lactobacillus plantarum

The invention discloses lactobacillus plantarum for relieving diarrhea caused by ETEC and application of the lactobacillus plantarum, and belongs to the technical field of microorganisms. The lactobacillus plantarum CCFM8661 with the effect of relieving the diarrhea caused by the ETEC is screened out, and the lactobacillus plantarum CCFM8661 is specifically embodied in that the weight loss of mice with the diarrhea caused by the ETEC and the increase of the water content of excrement are relieved; the content of pro-inflammatory cytokines IL-1beta, IFN-gamma, IL-6 and IL-8 in serum is obviously reduced; the content of immune factors IgA, IgG and IgM in serum is obviously increased; sT is reduced, and the level of AQP3 is increased; jejunum injury is relieved, and jejunum villus length shortening and crypt depth increasing caused by ETEC are remarkably improved; the gene expression quantity of tight junction proteins Claudin-1, ZO-1 and Occludin in jejunum tissues and mucoprotein MUC2 is remarkably increased, and the contents of acetic acid, propionic acid, isobutyric acid and butyric acid in excrement are remarkably increased.
Owner:JIANGNAN UNIV

Mussel mucoprotein loaded extracellular vesicle hydrogel as well as preparation method and application thereof

The invention relates to the technical field of hydrogel, in particular to mussel mucoprotein loaded extracellular vesicle hydrogel as well as a preparation method and application thereof. The hydrogel is prepared by adopting a mode of combining human umbilical cord mesenchymal stem cell exosome Exo and mussel mucoprotein MAP; the method has the following advantages: 1, the wound repair effect is improved: the biological activity of the exosome Exo and the adhesion performance of the mussel mucin MAP are utilized to jointly promote the wound repair process, so that the repair effect is improved; 2, the adhesion performance is enhanced: the strong adhesion of the mussel adhesive protein MAP is utilized to ensure that the hydrogel can be tightly attached to the wound surface in a wet environment, and the dressing is prevented from falling off and infection risk; and 3, multifunctionality is realized: the composite hydrogel not only has the basic functions of promoting healing, resisting bacteria and the like, but also can transmit genetic information through exosome Exo, so that tissue regeneration and skin barrier repair are further promoted.
Owner:GUANGXI XINYE BIOLOGICAL TECH +1

Ackermann muciniphile as well as regulator and application thereof

The invention relates to Ackermann muciniphile as well as a regulator and application thereof, and relates to the technical field of biochemistry. The invention provides application of ackermann muciniphile in preparation of drugs for treating anxiety, and the ackermann muciniphile can significantly improve exploration interest, significantly reduce anxiety level and reverse anxiety manifestation caused by chronic stress, which indicates that the ackermann muciniphile has an effect of treating anxiety. The invention also provides an application of the regulator in preparation of medicines or health-care foods for regulating intestinal flora. The regulator comprises cape jasmine and fermented soybean soup. The regulator can obviously increase the quantity of Ackerman muciniphile in the intestinal tract of a mouse, so that the intestinal health is improved, and the micro-ecological balance of the intestinal tract of a human body is regulated.
Owner:HEILONGJIANG ACAD OF TCM

Ackermann muciniphile, combined microbial agent thereof and application of ackermann muciniphile in inflammatory enteritis

The invention relates to the technical field of microorganisms, and discloses Ackermann muciniphila, a combined microbial agent thereof and application of the Ackermann muciniphila in inflammatory enteritis. The invention provides Akkermansia muciniphila AIML-559, and the preservation number of the Akkermansia muciniphila AIML-559 is CGMCC (China General Microbiological Culture Collection Center) No. 34246. The invention relates to a combined microbial agent, which is characterized by comprising Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34300). The combined microbial agent is prepared from the following raw materials: Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 The ackermann mucophil combined microbial inoculum is suitable for treatment intervention of inflammatory bowel disease (IBD), and can relieve weight loss, hemolysis, anemia, diarrhea, intestinal bleeding and other symptoms of IBD mice.
Owner:BEIJING YUANYANG XINGCHEN BIOTECHNOLOGY CO LTD

Application of garlic polysaccharide in preparation of product for repairing intestinal injury caused by constipation

The invention belongs to the technical field of biological medicine, and particularly relates to application of garlic polysaccharide in preparation of a product for repairing intestinal injury caused by constipation. An embodiment verifies that the garlic polysaccharide can effectively repair intestinal physical, chemical and immune barrier injuries caused by constipation, and by up-regulating expression of tight junction proteins (such as ZO-1 and Occludin) and reducing expression of Claudin-1, the garlic polysaccharide can enhance tight junction between intestinal epithelial cells and reduce intestinal permeability; besides, the garlic polysaccharide can promote secretion of intestinal mucoprotein and enhance the protection function of the intestinal mucous layer by up-regulating expression of MUC2 and MUC4 genes. The invention discloses a multi-aspect action mechanism of the garlic polysaccharide in repairing intestinal injury caused by constipation, and the garlic polysaccharide is expected to become a novel intestinal repairing agent for treating constipation and related complications thereof.
Owner:HEBEI UNIV OF ENG

Humanized antibodies to mucin-16 and methods of use thereof

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1

Isolated ackermansiella muciniphila, composition containing same and application of isolated ackermansiella muciniphila in preventing re-fatting

The invention provides isolated Ackermania muciniphila, a composition containing the same and application of the Ackermania muciniphila in preventing re-fatting. According to the present invention, the Akkermansia muciniphila has characteristics of high automatic aggregation ability and strong surface hydrophobicity, can effectively adhere to the intestinal epithelial cells, can prolong the intestinal retention time, and can improve the treatment effect. The strain adapts to the intestinal environment and is high in stability. The Akkermansia muciniphila disclosed by the invention can be used for remarkably inhibiting body weight rebound (reducing body weight growth rate and fat accumulation) after drug withdrawal, improving blood sugar steady state (reducing postprandial blood sugar and fasting blood sugar) and reducing visceral fat accumulation, and the action is lasting and does not rebound. An efficient and safe microbial therapy solution is provided for maintaining the body weight and preventing an easily-fat object from developing obesity after obesity treatment.
Owner:MOON (GUANGZHOU) BIOTECH CO LTD

Su semi-poria cocos and orange soup for relieving high secretion of mucus in acute exacerbation stage of chronic obstructive pulmonary disease as well as preparation method and application of Su semi-poria cocos and orange soup

The invention discloses a Su semi-poria cocos-tangerine decoction for relieving high secretion of mucus in an acute exacerbation stage of chronic obstructive pulmonary disease as well as a preparation method and application of the Su semi-poria cocos-tangerine decoction, and relates to the technical field of traditional Chinese medicine compositions. The Su semi-poria cocos and orange soup is prepared from 8-10 g of fructus perillae, 8-10 g of rhizoma pinellinae praeparata, 8-10 g of ginger processed cortex magnoliae officinalis, 8-10 g of radix peucedani, 4-6 g of fried semen brassicae, 8-10 g of fried semen raphani, 8-10 g of fried rhizoma atractylodis macrocephalae, 12-15 g of poria cocos, 4-6 g of fried pericarpium citri reticulatae and 2-3 g of cortex cinnamomi. Clinical application of the Su semi-poria cocos and tangerine decoction prepared by the invention shows that compared with a control group which is only treated by conventional western medicine, the secretion amount of mucoprotein MUC5AC is greatly reduced, traditional Chinese medicine symptom integral, CAT score and mMRC score are greatly reduced, symptoms of a patient are obviously relieved, and no adverse reaction occurs. Therefore, the Su semi-poria cocos and orange soup can relieve high secretion of mucus with the syndrome of AECOPD turbid phlegm obstructing lung and improve clinical symptoms of patients, and is good in safety.
Owner:JIANGSU PROVINCIAL HOSPITAL OF TCM

Composition for preventing and treating polycystic ovarian syndrome and application

The invention belongs to the technical field of biological medicine, and particularly relates to a composition for preventing and treating polycystic ovarian syndrome and application, the composition comprises the following active components: tripterygium wilfordii polysaccharide, dendrobium fimbriatum polysaccharide, hericium erinaceus polysaccharide, lycium barbarum polysaccharide and ackermania muciniphila bacterial suspension. A female SD rat model induced by letrozole and a high-glucose and high-fat feed is adopted to prove the application of Ackermania muciniphila in resisting the polycystic ovarian syndrome, the test method is safe and reliable, the test result is accurate, the curative effect is remarkable, and the invention provides a composition capable of inhibiting or improving or treating the polycystic ovarian syndrome. Compared with single oral administration of ackermania muciniphila suspension, the composition provided by the invention has the advantages that the effect is better, the components of the composition are safer, the technical problem that side effects exist when existing chemical synthesis medicines are used for treating the polycystic ovarian syndrome is solved, and the composition has a good application prospect.
Owner:WEIFANG MEDICAL UNIV

Yeast source mucoprotein with moisturizing effect and preparation method thereof

The invention relates to the field of biological moisturizing, in particular to yeast-source mucoprotein with a moisturizing effect and a preparation method thereof, and the preparation method comprises a recombinant strain construction method, a fermentation production method and a separation and purification method. The mucoprotein provided by the invention has good moisturizing performance, has large-scale industrial production capacity, and has good application prospects.
Owner:BAIKUIRI (TIANJIN) BIOTECHNOLOGY CO LTD

Application of lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Lucidophilic Ackermann strain and application of Lucidophilic Ackermann strain

The invention relates to the field of microorganisms, in particular to a mucophilic protein Ackermann strain and application thereof, and the preservation number of the mucophilic protein Ackermann strain is CCTCC (China Center for Type Culture Collection) NO: M 20241304. The Ackermania muciniphila AKK-86 disclosed by the invention has good effects of promoting iron absorption, improving iron metabolism and relieving intestinal inflammation at the same time. In addition, the Ackermansiella muciniphila can also promote the generation of GLP-1, and has the potential of application in the aspects of reducing blood sugar and losing weight products.
Owner:SHANGHAI ZHENGBAI BIOTECHNOLOGY CO LTD

Probiotic mucoprotein loaded oral microsphere system as well as preparation method and application thereof

The invention discloses a probiotic / mucoprotein loaded oral microsphere system as well as a preparation method and application thereof, and belongs to the field of compositions. The preparation method of the system comprises the following steps: dissolving probiotics, Mucin and HAMA in double distilled water containing phenyl lithium phosphate LAP and calcium chloride to prepare a gel matrix solution; adding the dissolved gel matrix liquid into an oil phase solvent, and stirring at a high speed in a container; after uniformly stirring, carrying out an ultraviolet light crosslinking reaction, and after the reaction is finished, fully cleaning the obtained microspheres to remove the redundant oil phase solution, so as to obtain microspheres; and dispersing the obtained microspheres in a sodium alginate solution under an acidic condition, uniformly mixing, carrying out a cross-linking reaction, and filtering and cleaning after the reaction is finished, so as to obtain the probiotic / mucoprotein loaded oral microspheres. According to the invention, HAMA and SA are utilized to prepare an oral microsphere system resistant to gastric acid to co-deliver Mucin and EcN, so as to realize continuous and effective regulation and control of unbalanced intestinal flora by probiotics.
Owner:CHINA PHARM UNIV

Compound hydrogel dressing based on recombinant mussel mucin and preparation method thereof

The invention relates to the technical field of medical dressings, and discloses a compound hydrogel dressing based on recombinant mussel mucin and a preparation method of the compound hydrogel dressing. The compound hydrogel based on the recombinant mussel mucin is prepared from the following raw material components in parts by weight: 0.01 to 0.3 part of the recombinant mussel mucin, 0.1 to 2.0 parts of a thickening agent, 10 to 21 parts of a polysaccharide composition, 1 to 8 parts of a humectant, 0.01 to 0.5 part of a pH (Potential of Hydrogen) regulator, 0.05 to 0.2 part of a preservative, 0.05 to 0.2 part of a metal ion chelating agent and 68 to 88 parts of purified water, the polysaccharide composition is prepared from glucan, chitosan and hyaluronic acid. The polysaccharide is compounded into the hydrogel of the recombinant mussel mucoprotein to play a role synergistically, and the polysaccharide and the recombinant mussel mucoprotein are closely combined and cross-linked, so that the adhesion of the compound hydrogel dressing is effectively improved, wound healing is promoted, the anti-inflammatory effect is improved, and meanwhile, a good protective barrier environment is formed for wound repair and healing.
Owner:SHENZHEN BAIYIN MEDICAL TECHNOLOGY CO LTD

A hybridoma cell line 6F92E10 and its monoclonal antibody and its application

The application discloses a hybridoma cell strain 6F92E10, a monoclonal antibody thereof and application thereof, and belongs to the technical field of biotechnology.The application provides a hybridoma cell strain secreting an anti-mucinophilic Akkermansia monoclonal antibody.The antibody secreted by the hybridoma cell strain only combines with AKKermansia and does not cross-react with other common intestinal bacteria.In addition, the application solves how to detect the adhesion and colonization of mucinophilic Akkermansia in the colon of a mouse by using the prepared monoclonal antibody through an indirect immunofluorescence localization experiment, and expands the application range of the antibody.
Owner:LINYI UNIVERSITY